-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Alvocidib
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/146426-40-6.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 146426-40-6 |
| Description | Alvocidib is a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. |
Product Information
| Synonyms | Flavopiridol; HMR 1275. HMR1275. HMR-1275. |
| Molecular Weight | 401.84 |
| Molecular Formula | C21H20ClNO5 |
| Canonical SMILES | CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O |
| InChI | InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1 |
| InChIKey | BIIVYFLTOXDAOV-YVEFUNNKSA-N |
| Boiling Point | 603.6±55.0 °C at 760 mmHg |
| Flash Point | 318.8±31.5 °C |
| Purity | 0.98 |
| Density | 1.4±0.1 g/cm3 |
| Solubility | In Vitro: DMSO : 33.33 mg/mL(82.94 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution |
| Appearance | Light yellow to yellow solid |
| Application | For research used only |
| Storage | 4°C, stored under nitrogen * In solvent : -80°C 6 months -20°C 1 month (stored under nitrogen) |
| Assay | The cells treated with flavopiridol are washed after 4 hours with PBS and resuspended in regular growth medium (RPMI 1640) supplemented with 10% human serum and antibiotics for the remainder of the incubation time. In the case of flavopiridol/chloroquine samples, chloroquine is re-added in the fresh media after flavopiridol is washed at 4 hours. For all the other conditions, cells are incubated with the respective drugs for 24 hours continuously. |
| Complexity | 628 |
| Exact Mass | 401.1030004 |
| Index Of Refraction | 1.673 |
| In Vitro | Flavopiridol (2 μM) robustly induces a distinct pattern of ER stress in CLL cells that contributes to cell death through IRE1-mediated activation of ASK1 and possibly downstream Caspases. Flavopiridol results in potent upregulation of a number of PRGs in treatments lasting 4-24 h. Flavopiridol has and immediate and long-term effect on the expression of several PRGs. In serum starved cells re-stimulated with serum, flavopiridol also inhibits the expression of these genes, but subsequently, JUNB, GADD45B and EGR1 are upregulated in the presence of flavopirido. |
| PSA | 94.14000 |
| Target | CDK1/Cyc B1:30 nM (IC50) CDK2/Cyc E:170 nM (IC50) CDK4/Cyc D1:100 nM (IC50) MAP:19000 nM (IC50) PKC:14000 nM (IC50) EGFR:22000 nM (IC50) |
| Vapor Pressure | 0.0±1.8 mmHg at 25°C |
| XLogP3-AA | 3.3 |
